<DOC>
	<DOC>NCT01220232</DOC>
	<brief_summary>This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.</brief_summary>
	<brief_title>Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Healthy male and/or female subjects. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Total body weight &gt;50 kg (110 lbs). History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening. Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day. Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication. History of hypersensitivity to abacavir, lamivudine and/or lersivirine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Lersivirine</keyword>
	<keyword>UK-453</keyword>
	<keyword>061</keyword>
	<keyword>NNRTI</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Combivir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
</DOC>